发明公开
- 专利标题： ANTIBODIES AGAINST FCRN AND USE THEREOF
- 专利标题（中）： 安东尼奥GEGEN FCRN UND DEREN VERWENDUNG
-
申请号： EP09734929.4申请日： 2009-04-24
-
公开(公告)号： EP2310415A2公开(公告)日： 2011-04-20
- 发明人: TENHOOR, Christopher , MURUGANANDAM, Arumugam , LADNER, Robert, Charles , WOOD, Clive , BITONTI, Alan, J. , STATTEL, James , MCDONNELL, Kevin , LIU, Liming , DUMONT, Jennifer , SATO, Aaron
- 申请人： Dyax Corporation , BIOGEN IDEC HEMOPHILIA INC.
- 申请人地址： 300 Technology Square Cambridge, MA 02139 US
- 专利权人： Dyax Corporation,BIOGEN IDEC HEMOPHILIA INC.
- 当前专利权人： Dyax Corporation,BIOGEN IDEC HEMOPHILIA INC.
- 当前专利权人地址： 300 Technology Square Cambridge, MA 02139 US
- 代理机构： Adams, Harvey Vaughan John
- 优先权： US48152P 20080425; US48500P 20080428
- 国际公布： WO2009131702 20091029
- 主分类号： C07K16/28
- IPC分类号： C07K16/28
摘要：
This disclosure provides, inter alia, proteins that bind to FcRn,
e.g. , immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
e.g. , immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
公开/授权文献
- EP2310415B8 ANTIBODIES AGAINST FCRN AND USE THEREOF 公开/授权日：2017-12-13
信息查询
